Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559983 | 0.94 | PTGS2 (0.45) | PTGS2PTGS1LMNAMAPTAKR1C3 | |
| SCHEMBL6425105 | 0.92 | AKR1C3 (0.41) | PTGS2PTGS1SRCPRKACAPRKACG | |
| SCHEMBL6426818 | 0.92 | SRC (0.41) | PTGS2PTGS1SRCPRKACAPRKACG | |
| SCHEMBL6425594 | 0.90 | SRC (0.44) | PTGS2PTGS1BCL2MDM2MCL1 | |
| SCHEMBL6425703 | 0.90 | BCL2 (0.32) | PTGS2PTGS1BCL2MDM2MCL1 | |
| SCHEMBL6426346 | 0.87 | PPARG (0.38) | PTGS2PTGS1LMNAMAPTAKR1C3 | |
| SCHEMBL6423032 | 0.87 | PPARG (0.40) | PTGS2PTGS1LMNAMAPTAKR1C3 | |
| SCHEMBL6425556 | 0.87 | BCL2 (0.40) | PTGS2BCL2MDM2MCL1SRC | |
| SCHEMBL6425666 | 0.87 | PTGS2 (0.47) | PTGS2PTGS1SRCLMNAMAPT | |
| SCHEMBL6425519 | 0.87 | PTGS2 (0.55) | PTGS2PTGS1LMNAMAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | PTGS2 4/4885PTGS1 7/4885BCL2 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.